(Sharecast News) - Shares in Silence Therapeutics more than doubled on Monday, after the US-listed British biotech agreed to be taken over by Germany's Merck in a $1.3bn deal.
Under the terms of the acquisition, Silence shareholders will receive $20 in cash per American depositary share, with each ADS representing three...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE